Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
05/2003
05/28/2003CN1420888A Substd. pyrazoloÒÇö4,3-eÒÇòdiazepines, pharmaceu-tical compositions contg. them, use as medicinal products and processes for preparing them
05/28/2003CN1420887A 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors
05/28/2003CN1420884A 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders
05/28/2003CN1420881A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha
05/28/2003CN1420879A Substd. pyridines and pyridazines with angiogenesis inhibiting activity
05/28/2003CN1420878A Compound with growth hormone releasing properties
05/28/2003CN1420872A Caspase inhibitors and use thereof
05/28/2003CN1420779A Nucleoside analogs with carboxamidine-modified bicyclic base
05/28/2003CN1420770A Method of delivery of cetyl myristoleate
05/28/2003CN1420755A Method and composition for treatment of scars
05/28/2003CN1420120A Medicinal preparation contg. 1-N-ethyl vistamycin or its salt, and process for preparing same
05/28/2003CN1419940A Medical ointment, film and tincture
05/28/2003CN1419920A Medicine for treating flat wart
05/28/2003CN1419919A 'Acne and rosacca aqueous powder' and 'acne and rosacca capsule' as medicine for treating acne and rosacca
05/28/2003CN1419915A External applied liquid medicine for treating psoriasis
05/28/2003CN1109548C Process for preparation of collagenous fibre tissue for animal's organs and blood vessels
05/27/2003US6570002 Inhibitor of programmed cell death
05/27/2003US6569900 Fulvic acid and its use in the treatment of various conditions
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569888 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis
05/27/2003US6569885 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569872 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569855 Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity
05/27/2003US6569842 Method of preparing and use of prodrugs of betulinic acid derivatives
05/27/2003US6569838 Excising the keloid to create a wound, and administering bacterial polysaccharide exotoxin (cm101) to reduce scarring at a site of the wound
05/27/2003US6569833 Given amino acid sequence; useful treating hyperproliferative disorders and in drug screening and drug design
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569437 Skin disorders
05/27/2003US6569410 Sun protection compositions containing UV protection factors and esters of hydroxycarboxylic acids and alk(en)yl oligoglycosides
05/27/2003CA2321829C Topical composition containing human epidermal growth factor
05/27/2003CA2273855C Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2209391C New heterocyclic biaryl compounds and their use in human or veterinary medicine and in cosmetics
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
05/27/2003CA2110119C Antiinflammatory and analgesic gel preparation
05/27/2003CA2031430C Process for refolding recombinantly produced tgf-.beta.-like proteins
05/22/2003WO2003042397A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042384A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof
05/22/2003WO2003042377A1 Expansion of t cells in vitro and expanded t cell populations
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042251A1 Chitosan compositions
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042179A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003WO2003042178A1 Novel piperidine derivatives as modulators of chemokine receptors
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042173A1 Nk1 antagonists
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041728A1 Novel phenyl-propargylether derivatives
05/22/2003WO2003041723A1 Pharmaceutical applications of hyaluronic acid preparations
05/22/2003WO2003041721A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041712A1 Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors
05/22/2003WO2003041708A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041704A1 Preventive or remedy for pruritus
05/22/2003WO2003041703A2 Use of a flavonoid for the treatment of burns
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041680A1 Topical compositions containing enzymes stabilized with inhibitors
05/22/2003WO2003041678A1 Carotenoid composition and method for protecting skin
05/22/2003WO2003041669A1 A composition for promoting hair growth
05/22/2003WO2003041660A2 Solubilized topoisomerase poisons
05/22/2003WO2003041651A2 Allatoin-containing skin cream
05/22/2003WO2003011277A3 Methods to mobilize progenitor/stem cells
05/22/2003WO2003009810A3 Silver alginate foam compositions
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002098438A9 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
05/22/2003WO2002089802A3 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/22/2003WO2002083120A3 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
05/22/2003WO2002053141A3 Inhibition of angiogenesis by nucleic acids
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003WO2000037429A3 INHIBITORS OF α4β1 MEDIATED CELL ADHESION
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030096998 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections
05/22/2003US20030096973 Recombinant collagens and derived proteins produced by plants, methods of obtaining such and their uses
05/22/2003US20030096871 Reduction of hair growth
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096850 Treating infections by administration of oxazolidinones
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096841 For treatment of cancers, heart disease, such as congestive heart failure, osteoporosis, genetic, inflammatory, allergic, and autoimmune diseases
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096811 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096769 Genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096752 Net charge of -3-3 at pH 7 and with the amino acids arginine15 or arginine15-alanine17 in the binding region; serine protease inhibitors
1 ... 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 ... 1065